136 related articles for article (PubMed ID: 23617506)
1. Evaluation of residual disease using breast MRI after excisional biopsy for breast cancer.
Chae EY; Cha JH; Kim HH; Shin HJ; Kim H; Lee J; Cheung JY
AJR Am J Roentgenol; 2013 May; 200(5):1167-73. PubMed ID: 23617506
[TBL] [Abstract][Full Text] [Related]
2. Postexcisional breast magnetic resonance imaging in patients with breast cancer: predictable findings of residual cancer.
Kim JA; Son EJ; Kim EK; Kim MJ; Kwak JY; Jeong J
J Comput Assist Tomogr; 2009; 33(6):940-5. PubMed ID: 19940664
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging of the breast in evaluating residual diseases at lumpectomy site soon after excisional biopsy.
Yang H; Liu H; Peng W; Hua Y
J Comput Assist Tomogr; 2012; 36(2):196-9. PubMed ID: 22446359
[TBL] [Abstract][Full Text] [Related]
4. MRI before reexcision surgery in patients with breast cancer.
Lee JM; Orel SG; Czerniecki BJ; Solin LJ; Schnall MD
AJR Am J Roentgenol; 2004 Feb; 182(2):473-80. PubMed ID: 14736685
[TBL] [Abstract][Full Text] [Related]
5. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging.
Frei KA; Kinkel K; Bonel HM; Lu Y; Esserman LJ; Hylton NM
AJR Am J Roentgenol; 2000 Dec; 175(6):1577-84. PubMed ID: 11090379
[TBL] [Abstract][Full Text] [Related]
6. Utility of breast MRI for evaluation of residual disease following excisional biopsy.
Wilkinson J; Appleton CM; Margenthaler JA
J Surg Res; 2011 Oct; 170(2):233-9. PubMed ID: 21550064
[TBL] [Abstract][Full Text] [Related]
7. MRI-detected suspicious breast lesions: predictive values of kinetic features measured by computer-aided evaluation.
Wang LC; DeMartini WB; Partridge SC; Peacock S; Lehman CD
AJR Am J Roentgenol; 2009 Sep; 193(3):826-31. PubMed ID: 19696298
[TBL] [Abstract][Full Text] [Related]
8. Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.
Yabuuchi H; Matsuo Y; Okafuji T; Kamitani T; Soeda H; Setoguchi T; Sakai S; Hatakenaka M; Kubo M; Sadanaga N; Yamamoto H; Honda H
J Magn Reson Imaging; 2008 Nov; 28(5):1157-65. PubMed ID: 18972357
[TBL] [Abstract][Full Text] [Related]
9. Breast MRI in the evaluation of locally recurrent or new breast cancer in the postoperative patient: correlation of morphology and enhancement features with the BI-RADS category.
Seely JM; Nguyen ET; Jaffey J
Acta Radiol; 2007 Oct; 48(8):838-45. PubMed ID: 17851971
[TBL] [Abstract][Full Text] [Related]
10. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance.
Sardanelli F; Fausto A; Esseridou A; Di Leo G; Kirchin MA
Invest Radiol; 2008 Apr; 43(4):236-42. PubMed ID: 18340247
[TBL] [Abstract][Full Text] [Related]
11. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement.
Gutierrez RL; DeMartini WB; Eby PR; Kurland BF; Peacock S; Lehman CD
AJR Am J Roentgenol; 2009 Oct; 193(4):994-1000. PubMed ID: 19770321
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the enhancing lesions on dynamic contrast enhanced magnetic resonance imaging in patients with interstitial mammoplasty.
Kim TY; Kim SH; Kang BJ; Kim HS; Cha ES; Kim JY; Song BJ
Eur J Radiol; 2013 Dec; 82(12):2205-11. PubMed ID: 24103354
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
Yi A; Cho N; Im SA; Chang JM; Kim SJ; Moon HG; Han W; Park IA; Noh DY; Moon WK
Radiology; 2013 Sep; 268(3):662-72. PubMed ID: 23592770
[TBL] [Abstract][Full Text] [Related]
14. Use of dynamic phase subtraction (DPS) map in dynamic contrast-enhanced MRI of the breast.
Ogura A; Hayakawa K; Yoshida S; Maeda F; Saeki F; Syukutani A
J Comput Assist Tomogr; 2011; 35(6):749-52. PubMed ID: 22082548
[TBL] [Abstract][Full Text] [Related]
15. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study.
Baltzer PA; Benndorf M; Dietzel M; Gajda M; Runnebaum IB; Kaiser WA
AJR Am J Roentgenol; 2010 Jun; 194(6):1658-63. PubMed ID: 20489110
[TBL] [Abstract][Full Text] [Related]
16. Effect of preoperative breast magnetic resonance imaging on surgical decision making and cancer recurrence rates.
Pediconi F; Miglio E; Telesca M; Luciani ML; Kirchin MA; Passariello R; Catalano C
Invest Radiol; 2012 Feb; 47(2):128-35. PubMed ID: 21934515
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.
Loo CE; Teertstra HJ; Rodenhuis S; van de Vijver MJ; Hannemann J; Muller SH; Peeters MJ; Gilhuijs KG
AJR Am J Roentgenol; 2008 Nov; 191(5):1331-8. PubMed ID: 18941065
[TBL] [Abstract][Full Text] [Related]
18. High-spatial-resolution 3-T breast MRI of nonmasslike enhancement lesions: an analysis of their features as significant predictors of malignancy.
Uematsu T; Kasami M
AJR Am J Roentgenol; 2012 May; 198(5):1223-30. PubMed ID: 22528918
[TBL] [Abstract][Full Text] [Related]
19. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.
Kinkel K; Helbich TH; Esserman LJ; Barclay J; Schwerin EH; Sickles EA; Hylton NM
AJR Am J Roentgenol; 2000 Jul; 175(1):35-43. PubMed ID: 10882243
[TBL] [Abstract][Full Text] [Related]
20. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
Javid S; Segara D; Lotfi P; Raza S; Golshan M
Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
